Emergent BioSolutions (EBS) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenues were $254.7M, exceeding guidance but down 25% year-over-year, with a net loss of $283.1M; adjusted EBITDA was $(10.1)M, impacted by one-time charges and settlement costs.

• Year-to-date 2024 revenues rose 11% to $555.1M, with net loss improving 39% to $(274.1)M compared to YTD 2023.

• Strategic actions included significant debt reduction, asset divestitures, operational streamlining, and a workforce reduction of ~50%.

• NARCAN® and MCM products remain core business drivers, with robust demand amid competitive pressures.

• The company faces substantial doubt about its ability to continue as a going concern due to liquidity constraints and upcoming debt maturities.

Financial highlights

• Q2 2024 total revenues were $254.7M, with Commercial Product sales at $120.0M (down 13%), MCM Product sales at $63.4M (down 61%), and Services revenue at $64.7M (up 122%).

• Adjusted EBITDA for Q2 2024 was $(10.1)M, down from $55.9M in Q2 2023, impacted by $28M in one-time charges.

• Total segment adjusted gross margin for Q2 2024 was 26%, down from 43% in Q2 2023.

• Cash and cash equivalents at June 30, 2024, were $69.7M; total debt stood at $862.2M.

• Net working capital at June 30, 2024, was $380M, improved by $53M from Q1.

Outlook and guidance

• FY 2024 revenue guidance raised to $1,050–$1,125M; adjusted EBITDA guidance increased to $140–$180M.

• Net loss forecast narrowed to $(314)–$(274)M for FY 2024.

• Q3 2024 revenue guidance set at $265–$315M.

• Commercial product sales expected at $450–$480M; MCM product sales at $455–$490M; Services segment revenue at $120–$130M.

• Continued focus on debt reduction, operational cash flow, and working capital improvements.